Could Jounce bounce away from Redx?

Today's Big News

Mar 15, 2023

Hookipa halts spending on cytomegalovirus vaccine after seeing phase 2 data


Bellicum’s GoCAR-Ts crash out of clinic over safety signal, sparking search for strategic alternatives


Mysterious biotech makes last-minute bid to snatch Jounce out of Redx’s hands


BioXcel takes surprising path with IPO of oncology spinout OnkosXcel


Armed with $105M and Big Pharma backing, Mediar takes aim at fibrotic mediators

 

Featured

Hookipa halts spending on cytomegalovirus vaccine after seeing phase 2 data

Hookipa Pharma’s hopes of partnering its cytomegalovirus (CMV) vaccine HB-101 have taken a hit, with final phase 2 data showing that giving two doses of the prophylactic prospect was no better at reducing viral infection than placebo in kidney transplant patients.
 

Top Stories

Bellicum’s GoCAR-Ts crash out of clinic over safety signal, sparking search for strategic alternatives

Bellicum Pharmaceuticals’ GoCAR-T cell therapies have skidded out, with the biotech halting trials of the two candidates over dose-limiting toxicities. The evaporation of Bellicum’s pipeline prompted the CAR-T cell therapy specialist to start an evaluation of strategic alternatives.

Mysterious biotech makes last-minute bid to snatch Jounce out of Redx’s hands

Just last month, Jounce Therapeutics jumped at the chance for a reverse merger into Redx Pharma after conceding its cancer meds were unlikely to advance any further into clinic. Now, the surprise arrival of another offer leaves Jounce in the unexpected position of fighting off prospective suitors.

Raw materials matter in mRNA vaccine and therapeutic development

In the development of mRNA vaccines and therapeutics, identifying a raw materials supplier who can partner with you from preclinical to commercial supply is a key to success.

BioXcel takes surprising path with IPO of oncology spinout OnkosXcel

In a move that analysts called surprising, BioXcel Therapeutics is moving immuno-oncology subsidiary OnkosXcel towards an IPO. 

Armed with $105M and Big Pharma backing, Mediar takes aim at fibrotic mediators

With a who’s who of Big Pharma on board and over $100 million in funds, Mediar Therapeutics is gearing up to see whether its first-in-class fibrosis therapies will deliver in the clinic.

AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate

Pfizer is the runaway winner of the United States’ first quarterly Who Can Raise Prices Higher Than the Rate of Inflation contest. Among 27 medicines whose price hikes exceeded the rate of inflation in the fourth quarter of 2022, Pfizer had five, which was three more than any other company. The list was released by the White House on Wednesday.

'Podnosis': Trends that should be on every hospital exec's radar, and the outlook for rural hospitals in 2023

This week on "Podnosis," we discuss strategies for hospital leaders to leverage this year given that 2022 went down as one of the most difficult years since the COVID-19 pandemic began. We also discuss the unique challenges rural hospitals face, particularly as pandemic-related funding dwindles.

In his first year as Johnson & Johnson CEO, Duato scored $13.1M payout

Joaquin Duato officially assumed Johnson & Johnson’s CEO position at the start of 2022, moving up from his prior role of vice chairman of the executive committee. But his pay package actually shrank in his first year as the company's top exec.

PerkinElmer completes $2.45B spinoff to create new diagnostics, life sciences company

Right on schedule, PerkinElmer has completed the split it announced last August, selling off its applied science, food and enterprise services businesses to private equity firm New Mountain Capital and combining the remaining life sciences and diagnostics businesses into a new, standalone company.

AbbVie, in fierce fight for eczema market, creates short documentary to show benefits of seeking help

What connects Chris Pine, the RZA and AbbVie? They all have films playing at South by Southwest (SXSW) 2023. The Big Pharma is using the event to debut a short documentary about how eczema affects the physical and emotional lives of three people.

Clever Care nabs $41M to scale up Medicare Advantage plans integrating Eastern and Western medicine

Clever Care Health Plan launched in 2020 with the aim of offering a holistic Medicare Advantage program for the growing number of beneficiaries interested in benefits that encompass Western clinical medicine and Eastern wellness benefits such as acupuncture. 
 
Fierce podcasts

Don't miss an episode

'The Top Line': AI and machine learning, plus the headlines

This week on "The Top Line," we take on AI and machine learning in the pharma and healthcare universe. The expectation is that these tools will speed up innovation and open up new markets, helping the sector stay ahead of the curve. Plus, this week's headlines.

 

Resources

Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.

Executive Summary

Optimizing drug discovery in a fast-moving market

Read about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines.
Whitepaper

Answering your specific questions about mRNA/saRNA manufacturing

Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here.
Whitepaper

Proven Pharmaceutical Go-To-Market Model

Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success.

Research

Strategizing for Clinical Trial Diversity

Like many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials.
Whitepaper

The Power of Small & Safety: Nanoplasmid™️ Vector Platform

Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies.

Whitepaper

Leveraging Archetypes for Effective Launch Strategy

Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches.
Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Research

Step-wise strategy to address process characterization and late phase development

Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development.

Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Research

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Case Study

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

 

Industry Events

 

Upcoming Fierce Events

14-15
Mar
San Francisco, CA
20-22
Mar
West Palm Beach, FL
3-4
Apr
San Diego, CA
1-3
May
May 1-3, 2023 | Jersey City, NJ
23
May
Free Virtual Event

View all events